IsoPlexis uses proteomics to identify early factors of long COVID

By Andre Rickard, The Science Advisory Board contributing writer

February 11, 2022 -- IsoPlexis has published a study in Cell, led by the Institute for Systems Biology and the Seattle COVID consortium, in which researchers used IsoPlexis' single-cell functional proteomics platform to identify factors that may predict sustained disease after COVID-19 infection, also known as post-acute sequelae of COVID-19 (PASC) or long COVID.

In the paper, researchers correlated patient symptoms with in-depth profiling of blood cells and plasma components throughout COVID-19 infection to identify factors associated with the development of PASC. PASC, the technical long COVID, is a range of new, returning, or ongoing health problems people can experience four or more weeks following infection. The authors followed 309 patients from initial clinical diagnosis to early-stage recovery from acute disease, spanning up to two to three months post-diagnosis, as well as 457 control patients.

Using IsoPlexis' single-cell functional proteomics platform, the researchers were able to identify correlations between the enhanced presence of certain polyfunctional immune cell types and the presentation of inflammation associated with PASC:

  • Increased frequency of "supervillain" T-cell subsets (CD4+ and CD8+ T cells) is positively associated with certain PASC symptoms/conditions, or endotypes, and disease severity at convalescence.
  • Similarly, the presence of "supervillain" monocytes in convalescent patients compared to healthy subjects is correlated with all of the major PASC endotypes, indicating the impact of monocytes on sustained inflammation at convalescence.
  • Natural killer cells in PASC endotypes played less of an active role in convalescence inflammation of PASC.

IsoPlexis' single-cell functional proteomics provided a unique assessment to dissect the functional impacts of different cell types across multiple time points and the interplay between innate and adaptive immune responses that contributed to effector functions or inflammation in PASC.

This study follows a previously published Immunity paper, where IsoPlexis' platform identified mechanisms of inflammation in moderate to severe cases of COVID-19.

IsoPlexis to present data at SITC 2021
IsoPlexis will present data from its IsoLight and IsoSpark platforms at the annual meeting of the Society for Immunotherapy of Cancer (SITC) on November...
IsoPlexis raises $125M in IPO
IsoPlexis completed an initial public offering (IPO) on October 12, closing with $125 million on the sale of approximately 8.3 million shares...
IsoPlexis acquires sequencing methodology IP
IsoPlexis has acquired an intellectual property (IP) portfolio of 86 patents related to DNA and RNA sequencing, which it is integrating into its single-cell...
IsoPlexis launches new COVID-19 proteomics grant challenge
IsoPlexis has unveiled its Single-Cell Proteomics COVID-19 Grant Challenge, which will award 12 of the company's IsoCode or CodePlex chips to two winners...
IsoPlexis partners with Columbia for vaccine development
IsoPlexis is partnering with Columbia University's Division of Infectious Diseases to create a vaccine for COVID-19. IsoPlexis' Single-Cell Secretome...

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter